Latest Insights on PGR
Banking’s $33.5 Trillion Is in Crypto’s Crosshairs September 24, 2024 Banyan Edge, Cryptocurrency, Investing “First they ignore you, then they laugh at you, then they fight you, then you win.” This is one of my favorite quotes. I’m not sure who said it, although it’s been incorrectly attributed to Mahatma Gandhi. To me, it describes the disruptive force of technology — incumbents ignore the upstarts, laugh at them, try to fend them off and then eventually lose to more efficient ways of doing things. This is exactly what’s happening in the world of traditional finance, as blockchains take aim at the $33.5 trillion financial sector.
The End of Nvidia’s Colossal 17,400% Run? August 22, 2024 Banyan Edge, Investing, Investment Opportunities If you'd invested just $3,600 in Nvidia back in 2016, your position would now be worth $642,000. Adam O'Dell takes a deeper look into one of the most successful tech breakouts in history, and gives you a clearer idea of whether there's more room to run, or better investments to be had elsewhere...
$37 Billion Breakthrough for American Semiconductor Industry August 13, 2024 Banyan Edge, Investment Opportunities, Trending The race for semiconductor dominance is going to be a critical mega trend in these early stages of the global AI boom. And the world's largest chipmaker is pouring more than $37 billion into upgrades and new facilities here in America. Could this change in strategy turn the tide for American chipmakers?
How One AI Model Beat 57,000 (Human) Competitors July 15, 2024 Artificial Intelligence, Banyan Edge, Investing, Investment Opportunities, Technology One AI model has helped researchers design new drugs, vaccines and enzymes. And it's just one example of a brand new industry within biotech.
Weight Loss Drug Like Ozempic Could Be the World’s First Trillion-Dollar Drug July 2, 2024 Banyan Edge, Diversified Investments, Investment Opportunities, Technology The FDA is on the cusp of an announcement that could create the first trillion-dollar drug -- out of GPL-1 class drugs like Ozempic.





